Announcements Trials
Browse Landscape

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 93Observational 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2

Interventions

Blood Specimen Collection 53Surveys and Questionnaires 49Specimen Handling 29Observation 15Radiotherapy 14Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 11Interviews as Topic 11Data Collection 11Drug Therapy 9darolutamide 8Biopsy 8palbociclib 7Watchful Waiting 7Tomography, X-Ray Computed 7Standard of Care 7ribociclib 6Magnetic Resonance Imaging 6Bevacizumab 6trastuzumab deruxtecan 5Ultrasonography 5Restraint, Physical 5Radiofrequency Ablation 5Patient Reported Outcome Measures 5Mental Status and Dementia Tests 5Mastectomy, Segmental 5Mass Screening 5Genetic Testing 5Breath Tests 5enzalutamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Fulvestrant × 90 days × Clear all
NCT04916509 2026-06-02

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

Pfizer

Completed
258 enrolled
Breast

Breast Neoplasms

NCT07347600 2026-05-18

reaINAVO

Hoffmann-La Roche

Recruiting
500 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡